Chronic Fatigue Syndrome News and Research

Latest Chronic Fatigue Syndrome News and Research

New research: Spinal fluid proteins can differentiate nPTLS from Chronic Fatigue Syndrome

Patients who suffer from Neurologic Post Treatment Lyme disease and those with the Chronic Fatigue Syndrome report similar symptoms. However unique proteins discovered in spinal fluid can distinguish those two groups from one another and also from people in normal health, according to new research conducted by a team led by Steven E. Schutzer, MD, of the University of Medicine and Dentistry of New Jersey - New Jersey Medical School, and Richard D. Smith, Ph.D., of Pacific Northwest National Laboratory.

24 Feb 2011

Chronic fatigue syndrome – eased by psychotherapy: Study

New British research suggests that people with chronic fatigue syndrome may be helped the most when standard treatment is coupled with cognitive behaviour therapy or exercise therapy.

20 Feb 2011

Chronic fatigue syndrome not linked to virus

The latest research from the University College London, the Wellcome Trust Sanger Institute, and University of Oxford, England suggests that chronic fatigue syndrome (CFS) is not caused by the virus XMRV (xenotropic murine leukemia virus-related virus). The team says that earlier research that linked the virus to CFS was faulty because of contamination of mouse cell DNA samples in the laboratory.

21 Dec 2010

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

Hemispherx Biopharma, Inc. announced that the Company has entered into an agreement with GP Pharm Latinoamerica, an affiliate company of Spanish GP Pharm SA for the marketing of Alferon N Injection®, the Company's natural interferon injection product which has been FDA approved for a category of sexually transmitted diseases in Argentina with an option for other Latin American countries upon receipt of those respective countries' regulatory approval for any use of the product.

21 Dec 2010

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.

14 Dec 2010

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Hemispherx Biopharma, Inc. announced that the Company has amended its June 15, 2010 agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com) to immediately include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement.

9 Dec 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research

Hemispherx Biopharma, Inc., announced the publication of a peer-reviewed article providing new data on Ampligen [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic in Phase III clinical testing, in the current issue of The Journal of Applied Research.

23 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Chronic fatigue syndrome associated with maladaptive personality features and personality disorders

This study suggests that chronic fatigue syndrome is associated with an increased prevalence of maladaptive personality features and personality disorders. This might be associated with being noncompliant with treatment suggestions, displaying unhealthy behavioral strategies and lacking a stable social environment.

8 Nov 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

Study finds cognitive behaviour therapy safe for chronic fatigue syndrome

The aim of this study is to examine the frequency and severity of symptom deterioration during cognitive behaviour therapy (CBT) for chronic fatigue syndrome (CFS). Patients receiving CBT do not experience more frequent or more severe symptom deterioration than untreated patients. The reported deterioration during CBT seems to reflect the natural variation in symptoms. Thus, CBT is not only a helpful, but also a safe treatment for CFS.

31 Aug 2010

Researchers find gene sequences of MLV in chronic fatigue syndrome patients' blood samples

Researchers have found murine leukemia viruses (MLV) related gene sequences in blood samples collected from patients diagnosed with chronic fatigue syndrome (CFS) and some healthy blood donors, according to a study published online today by the scientific journal Proceedings of the National Academy of Sciences (PNAS).

24 Aug 2010

NCF announces formal disease model for Chronic Fatigue Syndrome

The National CFIDS Foundation Inc., of Needham Mass, has announced its formal disease model for Chronic Fatigue Syndrome (CFS) also known as Chronic Fatigue Immune Dysfunction Syndrome (CFIDS) as well as Myalgic Encephalomyelitis (ME). According to the NCF, a subgroup of patients with CFS fit a unique disease profile based on a model for a radioactive toxin.

21 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Is the science of diagnosing pain causing a number of pain sufferers to defend their honor? Research out of the University of Cincinnati is examining the diagnosis of pain that evades scientific testing, and the additional emotional suffering that can result for the patient.

17 Aug 2010

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.

7 Aug 2010

Investment report on Hemispherx BioPharma

MicroStockProfit.com announces an investment report featuring Hemispherx BioPharma Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

7 Jul 2010

Chronic Fatigue Syndrome News and Research

Latest Chronic Fatigue Syndrome News and Research

New research: Spinal fluid proteins can differentiate nPTLS from Chronic Fatigue Syndrome

Chronic fatigue syndrome – eased by psychotherapy: Study

Chronic fatigue syndrome not linked to virus

Hemispherx to manufacture and supply Alferon N Injection to GP Pharm in Argentina

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

Hemispherx announces publication of Ampligen Phase III data in Journal of Applied Research

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Chronic fatigue syndrome associated with maladaptive personality features and personality disorders

New evidence supports possible link between XMRV and prostate cancer

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Study finds cognitive behaviour therapy safe for chronic fatigue syndrome

Researchers find gene sequences of MLV in chronic fatigue syndrome patients' blood samples

NCF announces formal disease model for Chronic Fatigue Syndrome

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Deconstruction of biomedical research on pain will improve diagnosis, treatment of chronic pain sufferers

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Investment report on Hemispherx BioPharma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chronic Fatigue Syndrome News and Research

Latest Chronic Fatigue Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in